Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Dyson Research Laboratories (Pvt.) Ltd

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000559 67 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx67product presentations
G32generic molecules
DF5dosage-form groups
TA9therapeutic areas
PKR67current price records
REG54registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage100%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixDyson Research Laboratories (Pvt.) LtdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/dyson-research-laboratories-pvt-ltdGenerated 10 Aug 2026Anti-infectives38 · 57%Vitamins, minerals & nutrition12 · 18%Gastrointestinal & hepatology5 · 7%Oncology & immunology4 · 6%Cardiovascular3 · 4%Reproductive & genitourinary2 · 3%Respiratory & allergy1 · 1%Other therapeutic areas2 · 3%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioDyson Research Laboratories (Pvt.) LtdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/dyson-research-laboratories-pvt-ltdGenerated 10 Aug 202667presentationsTablet38 · 57%Suspension10 · 15%Syrup9 · 13%Capsule7 · 10%Injection3 · 4%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionDyson Research Laboratories (Pvt.) LtdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/dyson-research-laboratories-pvt-ltdGenerated 10 Aug 202667comparable productsBelow market median13 · 19%Near market median23 · 34%Above market median31 · 46%Company median price position+4.3%Lowest-price equivalents4Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsDyson Research Laboratories (Pvt.) LtdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/dyson-research-laboratories-pvt-ltdGenerated 10 Aug 2026SAMI Pharmaceuticals Pvt. Ltd.27 shared84% overlapGenome Pharmaceuticals (Pvt.) Ltd,24 shared75% overlapM/s. Genix Pharma (Pvt) Ltd.23 shared72% overlapCCL Pharmaceuticals (Pvt.) Ltd.23 shared72% overlapNeutro Pharma (Pvt.) Ltd.,23 shared72% overlapShaigan Pharmaceuticals (Pvt) Ltd23 shared72% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives38 products · 57%
Vitamins, minerals & nutrition12 products · 18%
Gastrointestinal & hepatology5 products · 7%
Oncology & immunology4 products · 6%
Cardiovascular3 products · 4%
Reproductive & genitourinary2 products · 3%
Respiratory & allergy1 products · 1%
Pain & musculoskeletal1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Vitamins / minerals / hematinics12 products · 18%
Macrolide antibacterials9 products · 13%
Fluoroquinolone antibacterials9 products · 13%
Antivirals6 products · 9%
Third-generation cephalosporins5 products · 7%
Immunosuppressants / immunomodulators4 products · 6%
Beta blockers3 products · 4%
Antimalarials3 products · 4%
Formulation footprint

Dosage forms

Tablet38 products
Suspension10 products
Syrup9 products
Capsule7 products
Injection3 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 ZeproCiprofloxacin 6presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Tablet #2 AzigoldAzithromycin 4presentations 250 mg, 500 mg · Tablet #3 FantomaltIron polymaltose complex 4presentations 100 mg, 50 mg/5 mL · Tablet, Syrup #4 BisfatBisoprolol fumarate 3presentations 10 mg, 2.5 mg, 5 mg · Tablet #5 CefmanCefixime 3presentations 100 mg/5 mL, 200 mg/5 mL, 400 mg · Suspension, Capsule #6 ClariquenClarithromycin 3presentations 125 mg/5 mL, 250 mg, 500 mg · Suspension, Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1319% of comparable products
Near market median23within ±5% of median
Above market median3146% of comparable products
Lowest-price equivalents4ties included
Company median price position +4.3% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Virolok 400 mgRibavirin · Capsule · 10's PKR 18.21/capsule-68.2% vs market median Bisfat 10 mgBisoprolol fumarate · Tablet · 14's PKR 17.91/tablet-19.1% vs market median Azigold 500 mgAzithromycin · Tablet · 6's PKR 74.31/tablet-12.4% vs market median Azigold 250 mgAzithromycin · Tablet · 6's PKR 41.31/tablet-11.9% vs market median Daclavir 60 mgDaclatasvir · Tablet · 28's PKR 288.57/tablet-11.0% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

SAMI Pharmaceuticals Pvt. Ltd.188 products · 64 generics 27shared generics Genome Pharmaceuticals (Pvt.) Ltd,149 products · 71 generics 24shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 23shared generics CCL Pharmaceuticals (Pvt.) Ltd.243 products · 90 generics 23shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 23shared generics Shaigan Pharmaceuticals (Pvt) Ltd199 products · 75 generics 23shared generics
Regulatory & price activity

Observed database signals

Registration numbers54
Price-history records78
Products with price history11
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date30 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

38 results
Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Dysotam Tamoxifen 20 mg Tablet 30's 097673 PKR 881.65 PKR 29.39/tablet 6% above median
Dyzolid Linezolid 600 mg Tablet 12's 086306 PKR 4,485.46 PKR 373.79/tablet Near median
Dyzolid Linezolid 400 mg Tablet 12's 086305 PKR 2,562.11 PKR 213.51/tablet 8% below median
Gofung Dry Fluconazole 50 mg/5 mL Dry suspension 35 ml 074132 PKR 424.88 PKR 12.14/mL Near median
Ledisof Sofosbuvir 90 mg Tablet 28's 089965 PKR 51,593.30 PKR 1,842.62/tablet 9% below median
Levoson Levofloxacin 250 mg Tablet 10's 041581 PKR 476.14 PKR 47.61/tablet Near median
Levoson Levofloxacin 500 mg Tablet 10's 041582 PKR 792.30 PKR 79.23/tablet Near median
Mukil Itraconazole 100 mg Capsule 4's 055356 PKR 617.40 PKR 154.35/capsule 7% above median
OD-Cef Ceftriaxone 250 mg Injection 1's 045383 PKR 204.35 PKR 204.35/vial/unit 6% above median
OD-Cef Ceftriaxone 500 mg Injection 1's 078965 PKR 343.95 PKR 343.95/vial/unit 6% above median
Virohep Sofosbuvir 400 mg Tablet 28's 089962 PKR 11,018.43 PKR 393.52/tablet 8% below median
Virolok Ribavirin 400 mg Capsule 10's 062818 PKR 182.09 PKR 18.21/capsule 68% below median
Zepro Ciprofloxacin 500 mg Tablet 10's 041580 PKR 526.04 PKR 52.60/tablet 25% above median
Zepro Ciprofloxacin 250 mg Tablet 100's 041579 PKR 2,525.03 PKR 25.25/tablet Near median
Zepro Ciprofloxacin 250 mg Tablet 10's 041579 PKR 263.02 PKR 26.30/tablet Near median
Zepro Ciprofloxacin 500 mg Tablet 100's 041580 PKR 5,049.92 PKR 50.50/tablet 20% above median
Zepro Ciprofloxacin 250 mg/5 mL Suspension 60 ml 071307 PKR 323.72 PKR 5.40/mL 6% above median
Zepro Ciprofloxacin 125 mg/5 mL Suspension 60 ml 071306 PKR 222.36 PKR 3.71/mL Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.